An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states |
| |
| Authors: | R. de Beaurepaire A. Labelle B. D. Jones D. Naber T. R. E. Barnes |
| |
| Affiliation: | (1) INSERM U.320 & Groupement de Recherche Pharmacologique, Hôpital du Bon-Sauveur, 93, rue Caponière, 14012 Caen, France;(2) Royal Ottawa Hospital, 1145 Carling, KIZ 7K4 Ottawa, Ontario, Canada;(3) Psychiatrische Klinik und Poliklinik, Nussbaum Str. 7, D-80336 Munchen, Germany;(4) Gordon Hospital, Bloomburg Street, SW1V 2RH London, UK |
| |
| Abstract: | Six psychotic patients were included in a four-week study of the effects of the D1 selective antagonist SCH 39166 given as monotherapy. Four had a diagnosis of schizophrenia, and two suffered from a schizoaffective disorder. All presented with an acute psychotic exacerbation at the beginning of the trial. SCH 39166 was progressively increased from 50 mg/day to 600 mg/day. In the four schizophrenic patients, the BPRS worsened, and three out of the four failed to complete the study because of this. Three schizophrenic patients were aggressive or violent after abrupt discontinuation of treatment. In the two patients with schizoaffective disorder the BPRS improved during the trial, but they had an acute relapse immediately after treatment discontinuation. Extrapyramidal symptoms improved in three of the six patients, and worsened in one. |
| |
| Keywords: | Dopamine D1 receptor Antipsychotic Schizophrenia Schizoaffective disorder |
| 本文献已被 SpringerLink 等数据库收录！ |
|
